Clinical trial
An Open-Label, Dose Escalating Study to Evaluate the Safety of Intravaginal Oxybutynin in Subjects With Urge Urinary Incontinence
NCT00749632 is registered in ClinicalTrials.gov with FemmePharma Global Healthcare, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label, Dose Escalating Study to Evaluate the Safety of Intravaginal Oxybutynin in Subjects With Urge Urinary Incontinence
- Lead sponsor
- FemmePharma Global Healthcare, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 31, 2007
- Completion date
- October 31, 2008
- Enrollment
- 45 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.